PUBLISHER: GlobalData | PRODUCT CODE: 2027402
PUBLISHER: GlobalData | PRODUCT CODE: 2027402
Venous Thromboembolism (VTE): Epidemiology Forecast to 2034
Venous thromboembolism (VTE), comprised of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a potentially fatal condition which impedes blood flow by causing blood clots (thrombosis) (Wendelboe et al., 2021). In a VTE, a DVT is a clot that occurs only in the veins; DVT is commonly found in the legs and pelvis (proximally) but can also occur in the upper body (distally) (Henke et al., 2020). If the DVT travels from its original location through the circulatory system to the lungs, restricting, or blocking, blood supply, this is known as a PE (Henke et al., 2020; Patel et al., 2020). The clinical presentation of both DVT, and PE, is non-specific, at times asymptomatic, and can often result in sudden death. The high recurrence risk, and high mortality rate complicates the diagnostic and treatment process for VTE (Ageno et al., 2021).
GlobalData epidemiologists utilized comprehensive, country-specific VTE data from nationally representative, market-specific sources to forecast the diagnosed incident cases and attack rates of VTE in the 7MM. Robust nationally representative sources were used to forecast the medically ill population at risk of VTE, and the number of knee and hip replacements across the 7MM. Moreover, GlobalData epidemiologists provided detailed age- and sex-segmentations, with additional segmentation by anatomical region, provoking risk factor, and comorbidities (including cancer and CKD). Finally, historical data were evaluated in all 7MM to strengthen the forecast by more accurately capturing changes throughout the forecast period.
GlobalData epidemiologists forecast that the diagnosed incident cases of VTE will increase from 1,500,492 cases in 2024, to 1,710,302 cases in 2034, at an annual growth rate (AGR) of 1.41%. The number of VTE attacks is forecast to grow from 1,628,710 in 2024 to 1,859,433 in 2034 in the 7MM, at an AGR of 1.42%. GlobalData epidemiologists also forecast the number of medically ill patients at risk for VTE to increase in the 7MM from 14,454,096 in 2024 to 15,821,202 in 2034.
Scope
- VTE model and report provides an overview of the risk factors, comorbidities, and the global and historical trends for VTE in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident cases of PE, DVT, and VTE, each segmented by age and sex. Diagnosed incident cases of DVT is segmented by anatomical region and diagnosed incident cases of VTE by provoking risk factor. VTE recurrence at one and 10 years, VTE cases with cancer and chronic kidney disease as comorbidity, and the number of VTE attacks is also included.
- This report also includes a 10-year epidemiological forecast of medically ill patients discharged from hospital that are at risk for VTE, the number of primary total knee replacements and revisions, and the number of hip replacements.
Reasons to Buy
- Venous Thromboembolism Epidemiology series will allow you to:
- Develop business strategies by understanding the trends shaping and driving the global VTE markets.
- Quantify patient populations in the global VTE markets to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for VTE therapeutics in each of the markets covered.
- Understand magnitude of the VTE population by age, sex, anatomical region, comorbidity, and provoking risk factor.
Table of Contents
Table of Contents
1 Venous Thromboembolism (VTE): Executive Summary
- 1.1 Catalyst
- 1.2 Related reports
- 1.3 Upcoming reports
2 Epidemiology
- 2.1 Disease background
- 2.2 Risk factors and comorbidities
- 2.3 Global and historical trends
- 2.4 7MM forecast methodology
- 2.4.1 Sources
- 2.4.2 Forecast assumptions and methods
- 2.4.3 Diagnosed incident cases of PE, DVT, and VTE
- 2.4.4 Diagnosed incident cases of DVT by anatomical region
- 2.4.5 Diagnosed incident cases of VTE by provoking risk factor
- 2.4.6 Diagnosed incident cases of VTE with cancer as a comorbidity
- 2.4.7 Diagnosed incident cases of VTE with chronic kidney disease (CKD) as a comorbidity
- 2.4.8 Diagnosed VTE attacks
- 2.4.9 Number of one- and 10-year first-time recurrent cases of VTE
- 2.4.10 Number of hospital discharges meeting medically ill criteria
- 2.4.11 Number of hospital discharges meeting medically ill criteria at risk for VTE
- 2.4.12 Number of total hip and knee replacements
- 2.5 Epidemiological forecast for venous thromboembolism (VTE) (2024-34)
- 2.5.1 Diagnosed incident cases of PE
- 2.5.2 Diagnosed incident cases of DVT
- 2.5.3 Diagnosed incident cases of VTE
- 2.5.4 Age-specific diagnosed incident cases of VTE
- 2.5.5 Sex-specific diagnosed incident cases of VTE
- 2.5.6 Diagnosed incident cases of DVT by anatomical region
- 2.5.7 Number of diagnosed incident cases of VTE by provoking risk factor
- 2.5.8 One- and 10-year first-time diagnosed recurrent cases of VTE
- 2.5.9 Diagnosed incident cases of VTE with cancer as a comorbidity
- 2.5.10 Diagnosed incident cases of VTE with CKD as a comorbidity
- 2.5.11 Number of diagnosed VTE attacks
- 2.5.12 Number of hospital discharges meeting medically ill criteria at risk for VTE
- 2.5.13 Total number of hip replacements
- 2.5.14 Total number of knee replacements
- 2.6 Discussion
- 2.6.1 Epidemiological forecast insight
- 2.6.2 Limitations of the analysis
- 2.6.3 Strengths of the analysis
3 Appendix
- 3.1 Bibliography
- 3.2 About the authors
- 3.2.1 Epidemiologist
- 3.2.2 Reviewers
- 3.2.3 Vice President of Disease Intelligence and Epidemiology
- 3.2.4 Global Head of Pharma Research, Analysis, and Competitive Intelligence
- About GlobalData
- Contact Us
List of Table
List of Tables
- Table 1: Summary of updated data types
- Table 2: Risk factors and comorbidities for VTE
List of Figure
List of Figures
- Figure 1: 7MM, diagnosed incident cases of VTE, N, both sexes, all ages, 2024 and 2034
- Figure 2: 7MM, diagnosed incidence of PE, DVT, and VTE, cases per 100,000 population, both sexes, all ages, 2024
- Figure 3: 7MM, sources used and not used to forecast the diagnosed incident cases of PE, DVT, and VTE
- Figure 4: 7MM, sources used to forecast the diagnosed incident cases of DVT by anatomical region
- Figure 5: 7MM, sources used to forecast the diagnosed incident cases of VTE by provoking risk factor
- Figure 6: 7MM, sources used to forecast the diagnosed incident cases of VTE with cancer as a comorbidity
- Figure 7: 7MM, sources used to forecast the diagnosed incident cases of VTE with CKD as a comorbidity
- Figure 8: 7MM, sources used to forecast the diagnosed VTE attacks
- Figure 9: 7MM, sources used to forecast VTE recurrence after one and 10 years
- Figure 10: 7MM, sources used to forecast the number of hospital discharges that meet medically ill criteria and are at risk of VTE
- Figure 11: 7MM, sources used to forecast the primary total knee replacements and revisions, and hip replacements
- Figure 12: 7MM, diagnosed incident cases of PE, N, both sexes, all ages, 2024
- Figure 13: 7MM, diagnosed incident cases of DVT, N, both sexes, all ages, 2024
- Figure 14: 7MM, diagnosed incident cases of VTE, N, both sexes, all ages, 2024
- Figure 15: 7MM, diagnosed incident cases of VTE by age, N, both sexes, all ages, 2024
- Figure 16: 7MM, diagnosed incident cases of VTE by sex, N, both sexes, all ages, 2024
- Figure 17: 7MM, diagnosed incident cases of DVT by anatomical region, N, all ages, 2024
- Figure 18: 7MM, diagnosed incident cases of VTE by provoking risk factor, N, both sexes, all ages, 2024
- Figure 19: 7MM, first-time recurrent cases of VTE, N, both sexes, all ages, 2024
- Figure 20: 7MM, diagnosed incident cases of VTE with cancer as a comorbidity, N, both sexes, all ages, 2024 and 2034
- Figure 21: 7MM, diagnosed incident cases of VTE with CKD as a comorbidity, N, both sexes, 2024 and 2034
- Figure 22: 7MM, diagnosed VTE attacks, N, both sexes, all ages, 2024 and 2034
- Figure 23: 7MM, number of medically ill hospital discharges at risk for VTE, N, both sexes, >=40 years, 2024
- Figure 24: 7MM, total number of hip replacements, N, both sexes, >=15 years, 2024 and 2034
- Figure 25: 7MM, total number of knee replacements, N, both sexes, >=15 years, 2024 and 2034
